Abstract Cancer-specific TCF1+ stem-like CD8+ T cells can drive protective anticancer
immunity through expansion and effector cell differentiation,,–; however, this response is …

Expansion of antigen-experienced CD8+ T cells is critical for the success of tumour-
infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer. Interleukin-2 …

Tumour-infiltrating lymphocytes are associated with a survival benefit in several tumour
types and with the response to immunotherapy,,,,,,–. However, the reason some tumours …

Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to
directly recognize and kill tumour cells,–. These strategies are limited by the emergence of …

Cellular transformation induces phenotypically diverse populations of tumour-infiltrating T
cells,,,–, and immune checkpoint blockade therapies preferentially target T cells that …

Cancer arises from malignant cells that exist in dynamic multilevel interactions with the host
tissue. Cancer therapies aiming to directly kill cancer cells, including oncogene-targeted …

Group 2 innate lymphoid cells (ILC2s) regulate inflammation and immunity in mammalian
tissues,. Although ILC2s are found in cancers of these tissues, their roles in cancer immunity …

TGFβ signaling is associated with non-response to immune checkpoint blockade in patients
with advanced cancers, particularly in the immune-excluded phenotype. While previous …

T cells are important in tumour immunity but a better understanding is needed of the
differentiation of antigen-specific T cells in human cancer,. Here we studied CD8 T cells in …

The immune system uses two distinct defence strategies against infections: microbe-directed
pathogen destruction characterized by type 1 immunity, and host-directed pathogen …